Immunethep receives grant from Bill & Melinda Gates Foundation

Immunethep has received a grant from the Bill & Melinda Gates Foundation to test an antibody product included in its pipeline of antibacterial immunotherapies.
The company’s R&D and Intellectual Property is based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections.
Immunethep has been steadily advancing with its clinical roadmap which started with the PNV candidate vaccine that has successfully concluded pre-clinical trials.

Download the Press Release below:
Immunethep-BMGF_PressRelease_EN_20171023.pdf
Immunethep-BMGF_PressRelease_PT_20171023.pdf